<DOC>
	<DOCNO>NCT00490178</DOCNO>
	<brief_summary>The present study aim assess acceptability 4 week treatment new fixed-dose combination fenofibrate metformin , patient type 2 diabetes dyslipidemia</brief_summary>
	<brief_title>Acceptability Study New Fixed Combination Fenofibrate 80 mg BID Metformin 1000 mg BID Type 2 Diabetes Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>1 . Male female patient age 20 80 year ( inclusion visit ) . 2 . Type 2 diabetes treat stable dose metformin minimum 3 month either alone combination another oral hypoglycaemic agent . 3 . Dyslipidemia treat 160 mg fenofibrate ( bioequivalent formulation ) minimum 3 month either alone combination statin . 4 . And sign write informed consent . 1 . Known Type 1 Diabetes , uncontrolled type 2 diabetes [ HbA1c &gt; 9.5 % , Fasting plasma glucose ( FPG ) &gt; 240 mg/dL ( &gt; 13.4 mmol/L ) last performed blood sample ( within last 3 month ) ] . 2 . TG &gt; 500 mg/dL ( &gt; 5.65 mmol/L ) last performed blood sample ( within last 3 month ) . 3 . Women surgically sterilize ( i.e . bilateral tubal ligation , bilateral two unilateral oophorectomy , hysterectomy ) use adequate contraceptive method ( i.e . oral contraceptive , approve hormonal implant , intrauterine device , diaphragm spermicide , condom spermicide ) postmenopausal ( &gt; 1 year since last menstrual period ) . 4 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Type II diabetes</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>metformin</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>synordia</keyword>
</DOC>